|Articles|July 1, 2018

DL Test 13 071618

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

ByAndy Studna, Senior Editor

January 29th 2026

FDA Staffing Constraints Extend Planning and Review Timelines

ByCharlie Paterson,Andy Studna, Senior Editor

January 29th 2026

Worldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP Capabilities

ByAndy Studna, Senior Editor

January 28th 2026

How Real-World Evidence Will Change Trials Without Replacing Them

ByJen Lamppa,Andy Studna, Senior Editor

January 28th 2026

ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline

ByAndy Studna, Senior Editor

January 28th 2026

DL Test 13 071618

Newsletter

Related Content

FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development

FDA Staffing Constraints Extend Planning and Review Timelines

Worldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP Capabilities

How Real-World Evidence Will Change Trials Without Replacing Them

ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline

Trending on Applied Clinical Trials Online

Worldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP Capabilities

How Real-World Evidence Will Change Trials Without Replacing Them

ESG as a Quality System: Practical Steps to Embed Sustainability Into Vendor Oversight

What 2026 Will Demand From Clinical Operations: Rethinking Efficiency, Access, and AI

ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline